Prosecution Insights
Last updated: September 17, 2026
Application No. 17/926,359

ANTIBODY THAT BINDS SPECIFICALLY TO THE SARS COV 2 SPIKE PROTEIN, AND METHODS FOR ITS MANUFACTURE

Non-Final OA §OTHER
Filed
Nov 18, 2022
Priority
May 18, 2020 — EU 20175218.5 +2 more
Examiner
BELYAVSKYI, MICHAIL A
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ew Group GmbH
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
715 granted / 1114 resolved
+4.2% vs TC avg
Strong +28% interview lift
Without
With
+27.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
51 currently pending
Career history
1185
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
31.2%
-8.8% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
19.4%
-20.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1114 resolved cases

Office Action

§OTHER
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. Claims 1, 3, 5,6,10-12,14-16,18-30, 32-43 are pending. 2. Applicant’s election without traverse of Group I, claims 1,3,5,6,10-12,14-16,18-29 and 43, as it reads on SEQ ID N:30 in the reply filed on 11/07/25 is acknowledged. Claims 30, 32-42 are withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b) as being drawn to nonelected inventions. Claims 1,3,5,6,10-12,14-16,18-29 and 43, as it reads on SEQ ID N:30 are drawn to a method for isolating or producing an antibody are under consideration in the instant application. 3. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file. 4. Claims 1,3,5,6,10-12,14-16,18-29 and 43 are objected because they do not correspond to the scope of the elected Group I, as it reads on SEQ ID N: 30. Appropriate correction is required. 5. Claims 1, 3,5, 6,10-12,14-16,18-29 and 43 are objected to but would be allowable if rewritten in independent form to including all of the limitations of the elected claims as they read on SEQ ID N:30 and any intervening claims.
Read full office action

Prosecution Timeline

Nov 18, 2022
Application Filed
Feb 04, 2026
Non-Final Rejection mailed — §OTHER (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735497
BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
3y 5m to grant Granted Sep 15, 2026
Patent 12721890
T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53
3y 6m to grant Granted Sep 01, 2026
Patent 12698514
MAMMALIAN CELLS COMPRISING INTEGRATED CAS9 GENES TO PRODUCE STABLE INTEGRATION SITES, AND MAMMALIAN CELLS COMPRISING STABLE INTEGRATION SITES AND OTHER SITES
3y 9m to grant Granted Aug 04, 2026
Patent 12697388
CHIMERIC ANTIGEN RECEPTORS TARGETING CD127 AND USE THEREOF
3y 9m to grant Granted Aug 04, 2026
Patent 12692313
Chimeric Antigen Receptor (CAR) Comprising A CD19-Binding Domain
3y 6m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
92%
With Interview (+27.6%)
3y 1m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1114 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month